-transparent.png){kind=logo}
Cytotoxic effect in vitro and antitumor effect in vivo of doxorubicin (DOX) combined with cepharanthine were investigated on DOX-resistant murine P388 leukemia (P388/R) cells. Cepharanthine was minimally cytotoxic in the cell line, but reversed DOX-resistance in a dose-related manner in P388/R cells. The administration of cepharanthine to mice bearing the P388 leukemia enhanced the antitumor activity of DOX. These results indicate that cepharanthine is an effective agent to reverse DOX-resistant cells.
Related Publications
T Fujimura, and
H Shibata, and
I Maekawa, and
S Furusawa, and
H Kawauchi, and
K Sasaki, and
Y Takayanagi
January 1984,
Cancer research,
T Fujimura, and
H Shibata, and
I Maekawa, and
S Furusawa, and
H Kawauchi, and
K Sasaki, and
Y Takayanagi
October 1984,
Cancer research,
T Fujimura, and
H Shibata, and
I Maekawa, and
S Furusawa, and
H Kawauchi, and
K Sasaki, and
Y Takayanagi
February 1991,
Research communications in chemical pathology and pharmacology,
T Fujimura, and
H Shibata, and
I Maekawa, and
S Furusawa, and
H Kawauchi, and
K Sasaki, and
Y Takayanagi
September 1993,
Biulleten' eksperimental'noi biologii i meditsiny,
T Fujimura, and
H Shibata, and
I Maekawa, and
S Furusawa, and
H Kawauchi, and
K Sasaki, and
Y Takayanagi
January 1988,
Israel journal of medical sciences,
T Fujimura, and
H Shibata, and
I Maekawa, and
S Furusawa, and
H Kawauchi, and
K Sasaki, and
Y Takayanagi
November 1987,
The Journal of antibiotics,
T Fujimura, and
H Shibata, and
I Maekawa, and
S Furusawa, and
H Kawauchi, and
K Sasaki, and
Y Takayanagi
January 1985,
Cancer chemotherapy and pharmacology,
T Fujimura, and
H Shibata, and
I Maekawa, and
S Furusawa, and
H Kawauchi, and
K Sasaki, and
Y Takayanagi
June 1997,
Anti-cancer drug design,
T Fujimura, and
H Shibata, and
I Maekawa, and
S Furusawa, and
H Kawauchi, and
K Sasaki, and
Y Takayanagi
March 1991,
Biulleten' eksperimental'noi biologii i meditsiny,
T Fujimura, and
H Shibata, and
I Maekawa, and
S Furusawa, and
H Kawauchi, and
K Sasaki, and
Y Takayanagi
February 1986,
International journal of cancer,
